Healthy Skepticism Library

Items published during the years 2000 to 2009

There are 14385 items in the Healthy Skepticism Library that were published during the years 2000 to 2009.

Page 135 of 144 pages ‹ First  < 133 134 135 136 137 >  Last ›

HSL1658
Zwillicht T.
Congress to Seek $300 Billion for Medicare Benefit
Reuters Health 2002 Jan 28

HSL1660
Page S.
Drug ads: Saving lives, or selling snake oil?
The Ottawa Citizen 2002 Jan 28

HSL1924
Thomas PS, Tan KS, Yates DH.
Sponsorship, authorship, and accountability.
Lancet 2002 Jan 26; 359:(9303):351
http://linkinghub.elsevier.com/retrieve/pii/S0140673602075062

HSL1971
Peddicord D; Covance Inc; ICON Clinical Research; Inveresk Research Group; Kendle International, Inc; PAREXEL Internatinal Corporation; PPD Development; Quintiles Transnational Corporation.
Sponsorship, authorship, and accountability.
Lancet 2002 Jan 26; 359:(9303):350
http://linkinghub.elsevier.com/retrieve/pii/S0140673602075037

HSL6983
Di GIOVANNA.
Sponsorship, authorship, and accountability (3rd of 5 letters)
The Lancet 2002 Jan 26; 359:(350-351):

HSL6984
Kalman C.
Sponsorship, authorship, and accountability (5th of 5 letters)
The Lancet 2002 Jan 26; 359:(351-352):

HSL6985
Stonier P, Wells F.
Sponsorship, authorship, and accountability (2nd of 5 letters)
The Lancet 2002 Jan 26; 359:(350):

HSL1657
Freudenheim M.
Many H.M.O.'s for the Elderly Make Deep Cuts in Drug Aid
New York Times 2002 Jan 25
http://www.nytimes.com/2002/01/25/business/25CARE.html

HSL1964
Reidenberg MM.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24; 346:(4):290-2
http://content.nejm.org/cgi/content/extract/346/4/290

HSL6977
Holmer AF.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24; 346:(4):290-2

HSL6978
International COMMITTEE.
Sponsorship, authorship, and accountability (7th of 7 letters)
New England Journal of Medicine 2002 Jan 24; 364:(4):291-292

HSL6979
Landow L.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24; 346:(4):290-2

HSL6980
Loder E.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24; 346:(4):290-2

HSL6981
Peddicord D.
Sponsorship, authorship, and accountability (5th of 7 letters)
New England Journal of Medicine 2002 Jan 24; 346:(4):291

HSL6982
Relman AS.
Sponsorship, authorship, and accountability.
N Engl J Med 2002 Jan 24; 346:(4):290-2

HSL1656
Fraser M.
Drugs, ads and the 'direct' debate: Broadcasters want ability to peddle brand name drugs
Financial Post 2002 Jan 21

HSL1655
Brubaker B.
Drug Firms Still Lavish Pricey Gifts On Doctors Ethics Debated As Freebies Flow
Washington Post 2002 Jan 19
http://www.factsantidepressants.com/Drug-Firms-Still-Lavish-Pricey-Gifts-On-Doctors.htm

HSL1653
Corbey D
Patient doesn’t benefit from direct-to-consumer advertising
Opinion page NRC Handelsblad 2002 Jan 17

HSL17990
Kaufman DW, Kelly JP, Rosenberg L, Anderson TE, Mitchell AA.
Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey.
JAMA 2002 Jan 16; 287:(3):337-44
http://jama.ama-assn.org/cgi/content/full/287/3/337

HSL1652
US Docs Opt for Pricey Drugs for Urinary Infection
Reuters Health 2002 Jan 14

HSL1651
Barnes S.
Not a Generic Medicaid Director
New York Times 2002 Jan 13
http://www.nytimes.com/2002/01/13/business/private-sector-not-a-generic-medicaid-director.html?pagewanted=1

HSL17987
Marwick C.
Journal 'should have revealed scientist's connection to company'
BMJ 2002 Jan 12; 324:(7329):70
http://www.bmj.com/cgi/content/full/324/7329/70?view=long&pmid=11786448

HSL17988
Josefson D.
Drug companies face pressure on profits.
BMJ 2002 Jan 12; 324:(7329):65
http://www.bmj.com/cgi/content/full/324/7329/65?view=long&pmid=11786439

HSL1650
Debate opens on direct-to-consumer drug promotion in Europe
Press Release: Brussels 2002 Jan 11

HSL1569
The Bureau of National Affairs, Inc
Bush Signs Pediatric Incentive Bill Extending Exclusivity Provision Until 2007
2002 Jan 9

HSL1567
Petersen M.
Pfizer's Chief Is Subpoenaed in an Inquiry on Drug Pricing
New York Times 2002 Jan 8
http://www.nytimes.com/2002/01/08/business/08DRUG.html

HSL1568
FTC Questions Patent Listings on Brand-Name Prescription Drugs
Kaiser Daily Health Policy Report 2002 Jan 8

HSL17983
Laupacis A.
Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?
CMAJ 2002 Jan 8; 166:(1):44-7
http://www.cmaj.ca/cgi/content/full/166/1/44

HSL1566
Davis A.
'Postmarketing' by Makers of Alzheimer's Pill Raises Questions About the Uses of Research
The Wall Street Journal 2002 Jan 7
http://online.wsj.com/article/SB1010364361294762440.html?mod=googlewsj

HSL17391
Silverman E
Acne drug article under fire Link between author, company is criticized
The Star Ledger 2002 Jan 6

HSL17984
Sharma R
WHO calls for closer monitoring of commercial interests
BMJ 2002 Jan 5; 324:(7328):8
http://www.bmj.com/cgi/content/extract/324/7328/8/b

HSL1565
Gold R.
Federal Judge Lets Stand Florida Law Seeking Rebates From Drug Makers
The Wall Street Journal 2002 Jan 3
http://online.wsj.com/article/SB1010008142877430440.html?mod=googlewsj

HSL1982
Morin K, Rakatansky H, Riddick FA Jr, Morse LJ, O'Bannon JM 3rd, Goldrich MS, Ray P, Weiss M, Sade RM, Spillman MA.
Managing conflicts of interest in the conduct of clinical trials.
JAMA 2002 Jan 2; 287:(1):78-84
http://jama.ama-assn.org/cgi/content/full/287/1/78

HSL17986
Gelijns AC, Thier SO.
Medical innovation and institutional interdependence: rethinking university-industry connections.
JAMA 2002 Jan 2; 287:(1):72-7
http://jama.ama-assn.org/cgi/content/full/287/1/72

HSL17989
Tsai AC
Free Software and Physician Profiling
JAMA 2002 Jan 2; 287:(1):45
http://jama.ama-assn.org/cgi/content/extract/287/1/45

HSL1256
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA.
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
Am J Health Syst Pharm 2002 Jan 1; 59:(1):42-9
http://www.ajhp.org/cgi/reprint/59/1/42

HSL7799
Young D.
Studies show drug ads influence prescription decisions, drug costs.
Am J Health Syst Pharm 2002 Jan 1; 59:(1):14,
http://www.ajhp.org/cgi/reprint/59/1/14

HSL7800
Young D.
States form coalitions to leverage lower prescription drug prices.
Am J Health Syst Pharm 2002 Jan 1; 59:(1):20-1
http://www.ajhp.org/cgi/pmidlookup?view=reprint&pmid=11813461

HSL7817
Zachry WM 3rd, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA.
Relationship between direct-to-consumer advertising and physician diagnosing and prescribing.
Am J Health Syst Pharm 2002 Jan 1; 59:(1):42-9
http://www.ajhp.org/cgi/reprint/59/1/42

HSL1563
National Health.
Direct-To-Consumer Prescription Drug Advertising
2002 Jan
http://www.nationalhealthcouncil.org/advocacy/dtc_paper.htm

HSL1564
Norris P.
Talking the Talk
Prescriber Update 2002 Jan

HSL1840
Wolfe SM.
The destruction of medicine by market forces: teaching acquiescence or resistance and change?
Acad Med 2002 Jan; 77:(1):5-7
http://www.academicmedicine.org/cgi/content/full/77/1/5

HSL1930
Sumpradit N, Fors SW, McCormick L.
Consumers' attitudes and behavior toward prescription drug advertising.
Am J Health Behav 2002 Jan-Feb; 26:(1):68-75
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11795607

HSL1935
Simmer WS.
Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Manag Care Interface 2002 Jan; 15:(1):90-2
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11828611

HSL1978
National Health Council 2002 Jan;
http://www.nationalhealthcouncil.org/advocacy/DTC_paper.pdf

HSL25
Saver JL, Kidwell CS, Starkman S.
Commentary: thrombolysis in stroke: it works!
BMJ 2002; 324:727-729
http://bmj.bmjjournals.com/cgi/content/full/324/7339/723

HSL26
Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM.
Promotion of prescription drugs to consumers
N Engl J Med 2002; 346:498-505
http://content.nejm.org/cgi/content/abstract/346/7/498

HSL27
Mintzes B, Barer ML, Kravitz RL, Kazanjian A, Bassett K, Lexchin J, et al.
Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: two site cross sectional survey
BMJ 2002; 324:278-279
http://bmj.bmjjournals.com/cgi/content/full/324/7332/278

HSL29
Coyle SL.
Physician-industry relations. Part 2: organizational issues
Ann Intern Med 2002; 136:403-406
http://www.annals.org/cgi/reprint/136/5/403.pdf

HSL30
Coyle SL.
Physician-industry relations. Part 1: individual physicians
Ann Intern Med 2002; 136:396-401
http://www.annals.org/cgi/reprint/136/5/396.pdf

HSL31
Choudhry NK, Stelfox HT, Detsky AS
Relationships between authors of clinical practice guidelines and the pharmaceutical industry
JAMA 2002; 287:612-617
http://jama.ama-assn.org/cgi/content/full/287/5/612

HSL1654
Errett B.
What does it do? Um ... ask your doctor
National Post Date uncertain 2002

HSL1916
Warlow C.
Commentary: who pays the guideline writers
BMJ 2002; 324:726-727

HSL1918
Vlasov VV.
[Emerging problems of medical ethics in Russia: medical practice and research]
Kardiologiia. 2002;42(5):81-4. 2002; 42:(5):81-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12494154&query_hl=7

HSL1972
Pavenik N.
Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
Rand J Econ 2002 Aut; 33:(3):469-87
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12585303

HSL1977
Neubauer A.
[Consequences of the German anticorruption law for sponsorship at university hospitals].
Wien Med Wochenschr 2002; 152:(9-10):246-8
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1563-258X.2002.02038.x

HSL2027
Menon AM, Deshpande AD, PerriM 3rd, inkhan M.
Trut in onine precriptio drug iformation among internet users: the impact on information search behavir afterexposur to dirct-to-cnsumer
dvertis ng.
He
lth Mark Q 2002; 20:(1):17-35
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?md=Retr eve&db=ubmed&dpt=Abstact&lis_uids=1749596

HSL2098
Shakir SA, Layton D.
Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria.
Drug Saf 2002; 25:(6):467-71

HSL2134
De Latt, Windmeijer F, Douven R.
How does pharmaceutical marketing influence doctors' prescribing behaviour?
The Hague: CPB Netherlands Bureau for Economic Policy Analysis 2002
http://www.cpb.nl/nl/pub/bijzonder/38

HSL2147
Families USA.
Profiting from pain: where prescription drug dollars go. Families USA Publication No. 02- 105.
Washington, DC: Families USA 2002 07
http://www.familiesusa.org/site/DocServer/PPreport.pdf?docID=249

HSL2148
WHO Department of Essential Drugs & Medicines Policy
Drug Promotion Database
: WHO Department of Essential Drugs & Medicines Policy 2002
http://www.drugpromo.info/

HSL2202
Lyles A.
Direct marketing of pharmaceuticals to consumers.
Annu Rev Public Health 2002; 23:73-91:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11910055

HSL2244
Lefebvre T.
[Archeology of the radio pharmaceutical advertisement].
Rev Hist Pharm (Paris). 2002; 50:(336):647-64
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12731488

HSL2254
Kind M.
[Physicians--victims or promoters of corruption?].
Wien Med Wochenschr. 2002; 152:(9-10):249-52
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094402

HSL2255
Kemper DW, Mettler M.
A consumer-empowered response to direct-to-consumer advertising of prescription drugs.
Manag Care Q 2002 Spring; 10:(2):52-4
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12148483

HSL2446
Jedrey CM, Chaurette KA, Winn LB.
Pharmaceutical company-sponsored disease management programs.
Manag Care Q 2002 Win; 10:(1):56-60
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476660http://

HSL2448
Isidor JM, Kaltman SP.
Fast track to disaster? Considerations raised by the current recruitment techniques for clinical research subjects
J Biolaw Bus 2002; 5:(3):46-7
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12816118

HSL2450
Health Action International.
The Erice Statement on drug advertising to consumers
2002;
http://www.haiweb.org/campaign/DTCA/EriceStatement2002.doc

HSL2453
Hosch H.
[Research support and the pharmaceutical industry in Germany.]
Wien Med Wochenschr. 2002; 152:(9-10):238-40
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094398

HSL2454
Hoogenberg K, van der Tuin J.
[Misleading advertising claims about the indication of doxazosin (Cardura) for type 2 diabetes mellitus and hypertension].
Ned Tijdschr Geneeskd. 2002 November 2; 146:(44):2099-100
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12448967

HSL2457
Hochhauser M.
Which prescription for the illegible and unreadable DTC (direct-to-consumer) brief summary--major surgery or euthanasia?
Manag Care Q 2002 Sum; 10:(3):6-10
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12476659

HSL2458
Hirsch LJ.
Conflicts of interest in drug development: the practices of Merck & Co., Inc
Sci Eng Ethics 2002 July; 8:(3):429-42
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12353373

HSL2460
Healy DI.
Conflicting interests in Toronto: anatomy of a controversy at the interface of academia and industry.
Perspect Biol Med 2002 Spr; 45:(2):250-63
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=11919383

HSL2462
Graber MA, Weckmann M.
Pharmaceutical company internet sites as sources of information about antidepressant medications.
CNS Drugs 2002; 16:(6):419-23
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12027787

HSL2463
Golden GA, Parochka JN, Overstreet KM.
Medical education and communication companies: an updated in-depth profile.
J Contin Educ Health Prof 2002 Win; 22:(1):55-62
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12004641

HSL2467
Findlay S.
Do ads really drive pharmaceutical sales? The true effects of DTC advertising remain a mystery
Mark Health Serv. 2002 Spr; 22:(1):20-25

HSL2487
Carter T.
What can Johnson & Johnson do to remain a giant in the health care industry?
J Hosp Mark Public Relations 2002; 14:(1):93-103
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12569997

HSL2488
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002; 20:(15 Supplement 3):77-85
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12457428

HSL2493
Bojunga G.
[Is research in Germany up for sale?
Results of a study of Transparency International Germany]Wien Med Wochenschr 2002; 152:(9-10):244-5
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12094400

HSL2494
Bode UH, Geisler EP.
[Medical ethics as output of economically motivated industrial objectives].
Wien Med Wochenschr. 2002; 152:(13-14):309-12
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12168510

HSL2498
Baird PA.
Identification of genetic susceptibility to common diseases: the case for regulation.
Perspect Biol Med 2002 Fal; 45:(4):516-28
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12388884

HSL2500
Allen AJ, Michelson D.
Drug development process for a product with a primary pediatric indication.
J Clin Psychiatry 2002; 63:44-9
http://www.psychiatrist.com/pcc/pccpdf/v04s04/v63s1207.pdf

HSL3698
Innvaer S, Vist G, Trommald M, Oxman A.
Health policy-makers’ perceptions of their use of evidence: a systematic review.
J Health Ser Res Policy. 2002; 4:239–244

HSL3702
Coney S.
Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand.
J Public Policy Market. 2002; 21:213–223.

HSL3814
Is Yasmin a "truly different" pill?
Drug Ther Bull 2002; 40:(8):57-9
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=12216337

HSL4519
O'Keefe DJ.
Persuasion: Theory & Research 2nd Edn.
Thousand Oaks: Sage 2002

HSL4581
Kamm MA.
Pharmacological treatment of irritable bowel syndrome--from concept to sales.
Eur J Surg Suppl 2002; (587):10-5

HSL4822
Ghosh S.
Pills, patents, and power: state creation of gray markets as a limit on patent rights.
Fla J Int Law 2002 Spr; 14:(2):217-60

HSL4823
Nagan WP.
International intellectual property, access to health care, and human rights: South Africa v. United States.
Fla J Int Law 2002 Spr; 14:(2):155-91

HSL5662
Nakamura L.
Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. [Review of: Wilson, R. Pious traders in medicine: a German pharmaceutical network in eighteenth-century North America. University Park, Pa.: Penn State Pr., 2000]
J South Hist. 2002; 68:(3):677-8

HSL7458
Palumbo FB, Mullins CD.
The Development of Direct-to-Consumer Prescription Drug Advertising Regulation
Food and Drug Law Journal 2002; 57:(3):423-443
http://www.kff.org/rxdrugs/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=14372

HSL7625
Lexchin J.
Should doctors be prescribing new drugs?
International Journal of Risk and Safety in Medicine 2002; 15:(3-4):213-222

HSL7628
Lawrence LW.
A study of consumer recall of prescription medication advertisements
Journal of Pharmaceutical Marketing and Management 2002; 15:(1):52-58

HSL7629
Spiller LD, Wymer WW.
Physicians' responses to marketing strategies of pharmaceutical companies
Journal of Pharmaceutical Marketing and Management 2002; 15:(1):15-30

HSL7640
Mossialos E, Mrazek MF.
Data needed for developing and monitoring policies
International Journal of Risk and Safety in Medicine 2002; 15:(1-2):15-27

HSL7652
Vivian JC.
Federal limits on gifts from pharmaceutical companies
US Pharmacist 2002; 27:(11):96-98,101

HSL7654
Adcock H.
Pharmageddon: is it too late to tackle growing resistance to anti-infectives?
Pharmaceutical Journal 2002; 269:(7221):599-600

HSL7656
Goeschl T.
Stakes in the evolutionary race: The economic value of plants for medicinal applications
Journal of Herbs Spices and Medicinal Plants 2002; 9:(4):373-388

HSL7657
Koch YD, Ernst ME, Kelly MW.
Patient perceptions about drug advertising and prescription-to-nonprescription switches
American Journal of Health System Pharmacy 2002; 59:(16):1568

HSL7659
Drife J.
Oral contraception and the risk of thromboembolism: what does it mean to clinicians and their patients?
Drug Saf 2002; 25:(13):893-902

Page 135 of 144 pages ‹ First  < 133 134 135 136 137 >  Last ›